Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 1
1996 2
1998 2
1999 2
2001 1
2002 1
2006 2
2007 4
2008 4
2009 3
2010 3
2011 2
2013 2
2014 5
2015 3
2016 1
2017 6
2018 5
2019 6
2020 9
2021 11
2022 7
2023 19
2024 13
2025 14
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Results by year

Filters applied: . Clear all
Page 1
Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review.
Kim PS, Fishman MA. Kim PS, et al. Curr Pain Headache Rep. 2020 Aug 26;24(10):64. doi: 10.1007/s11916-020-00898-0. Curr Pain Headache Rep. 2020. PMID: 32845365
PURPOSE OF REVIEW: The purpose of this review is to evaluate and explain our current understanding of the clinical use of low-dose naltrexone in the treatment of chronic pain. RECENT FINDINGS: Recent pre-clinical uses and clinical studies furthe …
PURPOSE OF REVIEW: The purpose of this review is to evaluate and explain our current understanding of the clinical use of low-dose …
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
Younger J, Parkitny L, McLain D. Younger J, et al. Clin Rheumatol. 2014 Apr;33(4):451-9. doi: 10.1007/s10067-014-2517-2. Epub 2014 Feb 15. Clin Rheumatol. 2014. PMID: 24526250 Free PMC article. Review.
Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome. ...LDN may represent one of the first glial cell modulators to be us …
Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn's …
The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders.
Patten DK, Schultz BG, Berlau DJ. Patten DK, et al. Pharmacotherapy. 2018 Mar;38(3):382-389. doi: 10.1002/phar.2086. Epub 2018 Feb 23. Pharmacotherapy. 2018. PMID: 29377216 Review.
It is the purpose of this review to examine the evidence of the safety, tolerability, and efficacy of low-dose naltrexone for use in chronic pain and inflammatory conditions. Currently, evidence supports the safety and tolerability of low …
It is the purpose of this review to examine the evidence of the safety, tolerability, and efficacy of low-dose naltrexone …
Low Dose Naltrexone In The Management Of Chronic Pain Syndrome: A Meta-Analysis Of Randomized Controlled Clinical Trials.
Hegde NC, Mishra A, V D, Maiti R, Hota D, Srinivasan A. Hegde NC, et al. Curr Pain Headache Rep. 2025 Jun 20;29(1):96. doi: 10.1007/s11916-025-01411-1. Curr Pain Headache Rep. 2025. PMID: 40540205
OBJECTIVE: Chronic pain conditions are among the leading causes of years lost to disability. Low Dose Naltrexone (LDN) has anti-inflammatory and immunomodulatory properties. LDN, by blocking Toll-Like Receptors (TLR), prevents central sensitizat …
OBJECTIVE: Chronic pain conditions are among the leading causes of years lost to disability. Low Dose Naltrex …
Low-dose Naltrexone Improves post-COVID-19 condition Symptoms.
Tamariz L, Bast E, Klimas N, Palacio A. Tamariz L, et al. Clin Ther. 2024 Mar;46(3):e101-e106. doi: 10.1016/j.clinthera.2023.12.009. Epub 2024 Jan 23. Clin Ther. 2024. PMID: 38267326
The relative hazard of improvement for those taking low-dose naltrexone was 5.04 (95% CI, 1.22-20.77; P = 0.02) compared with physical therapy alone. Both fatigue and pain were improved in patients taking low-dose naltrexone; only …
The relative hazard of improvement for those taking low-dose naltrexone was 5.04 (95% CI, 1.22-20.77; P = 0.02) compare …
Low-dose naltrexone as a treatment for chronic fatigue syndrome.
Bolton MJ, Chapman BP, Van Marwijk H. Bolton MJ, et al. BMJ Case Rep. 2020 Jan 6;13(1):e232502. doi: 10.1136/bcr-2019-232502. BMJ Case Rep. 2020. PMID: 31911410 Free PMC article.
Naltrexone is used as an off-label treatment in low doses for several chronic immune-modulated disorders in many countries. ...Despite numerous internet reports of response to low-dose naltrexone (LDN), no clinical trials exist in people …
Naltrexone is used as an off-label treatment in low doses for several chronic immune-modulated disorders in many countr …
Low-Dose Naltrexone Use for Patients with Chronic Regional Pain Syndrome: A Systematic Literature Review.
Soin A, Soin Y, Dann T, Buenaventura R, Ferguson K, Atluri S, Sachdeva H, Sudarshan G, Akbik H, Italiano J. Soin A, et al. Pain Physician. 2021 Jul;24(4):E393-E406. Pain Physician. 2021. PMID: 34213865 Free article.
OBJECTIVE: The goal of this systematic qualitative review is to evaluate the evidence for the use of low-dose naltrexone in the treatment of chronic pain syndromes. STUDY DESIGN: This is a systematic review. ...We found that low-dose …
OBJECTIVE: The goal of this systematic qualitative review is to evaluate the evidence for the use of low-dose naltrexone …
Low-Dose Naltrexone in Chronic Pain Management: Mechanisms, Evidence, and Clinical Implications.
McKenzie A, Bittar T, Dombrower R, Raman D, Hussain H, Theeraphapphong N, McKenzie SM, Abd-Elsayed A. McKenzie A, et al. J Pers Med. 2026 Mar 6;16(3):151. doi: 10.3390/jpm16030151. J Pers Med. 2026. PMID: 41893019 Free PMC article. Review.
Chronic pain imposes a substantial burden on global health and remains challenging to manage, despite ongoing advances in pharmacologic and interventional therapies. ...Available clinical evidence evaluating LDN across a range of chronic pain condition …
Chronic pain imposes a substantial burden on global health and remains challenging to manage, despite ongoing advances in phar …
Complex Regional Pain Syndrome: A Comprehensive Review.
Taylor SS, Noor N, Urits I, Paladini A, Sadhu MS, Gibb C, Carlson T, Myrcik D, Varrassi G, Viswanath O. Taylor SS, et al. Pain Ther. 2021 Dec;10(2):875-892. doi: 10.1007/s40122-021-00279-4. Epub 2021 Jun 24. Pain Ther. 2021. PMID: 34165690 Free PMC article. Review.
Complex regional pain syndrome (CRPS) is a chronic pain condition often involving hyperalgesia and allodynia of the extremities. ...Antioxidant treatment has also shown some promise. Other pharmacotherapies include low-dose naltrexone and …
Complex regional pain syndrome (CRPS) is a chronic pain condition often involving hyperalgesia and allodynia of the ext …
Evaluation of Low-Dose Naltrexone for Chronic Pain Management.
Spargo A, Gonser L, Faley B. Spargo A, et al. J Pain Palliat Care Pharmacother. 2025 Jun;39(2):319-322. doi: 10.1080/15360288.2025.2456279. Epub 2025 Feb 3. J Pain Palliat Care Pharmacother. 2025. PMID: 39901608
While several studies show the promise of low-dose naltrexone in treating chronic pain, most had small sample sizes and short-term follow up, which warrants additional investigation into the effectiveness of low-dose naltrexone …
While several studies show the promise of low-dose naltrexone in treating chronic pain, most had small sa …
129 results